![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PAGE2B |
Gene summary for PAGE2B |
![]() |
Gene information | Species | Human | Gene symbol | PAGE2B | Gene ID | 389860 |
Gene name | PAGE family member 2B | |
Gene Alias | CT16.5 | |
Cytomap | Xp11.21 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q5JRK9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
389860 | PAGE2B | HCC2 | Human | Liver | HCC | 8.19e-10 | 2.84e+00 | 0.5341 |
389860 | PAGE2B | S014 | Human | Liver | HCC | 9.74e-67 | 2.99e+00 | 0.2254 |
389860 | PAGE2B | S015 | Human | Liver | HCC | 5.98e-31 | 2.98e+00 | 0.2375 |
389860 | PAGE2B | S016 | Human | Liver | HCC | 2.92e-72 | 3.11e+00 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAGE2B | SNV | Missense_Mutation | novel | c.59C>T | p.Ser20Phe | p.S20F | Q5JRK9 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PAGE2B | SNV | Missense_Mutation | c.208N>A | p.Ala70Thr | p.A70T | Q5JRK9 | protein_coding | tolerated(0.05) | probably_damaging(0.997) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
PAGE2B | SNV | Missense_Mutation | c.35N>T | p.Ser12Leu | p.S12L | Q5JRK9 | protein_coding | tolerated(0.11) | benign(0.009) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PAGE2B | SNV | Missense_Mutation | novel | c.37N>A | p.Glu13Lys | p.E13K | Q5JRK9 | protein_coding | tolerated(0.41) | benign(0.017) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
PAGE2B | SNV | Missense_Mutation | novel | c.197N>A | p.Pro66His | p.P66H | Q5JRK9 | protein_coding | deleterious(0.01) | benign(0.353) | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
PAGE2B | SNV | Missense_Mutation | novel | c.77N>A | p.Ser26Tyr | p.S26Y | Q5JRK9 | protein_coding | deleterious(0.02) | possibly_damaging(0.549) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
PAGE2B | SNV | Missense_Mutation | novel | c.52N>A | p.Gln18Lys | p.Q18K | Q5JRK9 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-D1-A1NZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAGE2B | SNV | Missense_Mutation | novel | c.166G>A | p.Glu56Lys | p.E56K | Q5JRK9 | protein_coding | tolerated(0.35) | benign(0) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
PAGE2B | SNV | Missense_Mutation | novel | c.28N>A | p.Gln10Lys | p.Q10K | Q5JRK9 | protein_coding | tolerated(1) | probably_damaging(0.981) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
PAGE2B | SNV | Missense_Mutation | c.226G>T | p.Ala76Ser | p.A76S | Q5JRK9 | protein_coding | tolerated(0.26) | probably_damaging(0.996) | TCGA-63-5131-01 | Lung | lung squamous cell carcinoma | Male | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |